"Haloperidol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
| Descriptor ID |
D006220
|
| MeSH Number(s) |
D02.522.352.506
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Haloperidol".
Below are MeSH descriptors whose meaning is more specific than "Haloperidol".
This graph shows the total number of publications written about "Haloperidol" by people in this website by year, and whether "Haloperidol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 2 | 4 |
| 1994 | 1 | 1 | 2 |
| 1995 | 3 | 0 | 3 |
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Haloperidol" by people in Profiles.
-
Uzuneser TC, Weiss EM, Dahlmanns J, Kalinichenko LS, Amato D, Kornhuber J, Alzheimer C, Hellmann J, Kaindl J, Hübner H, Löber S, Gmeiner P, Grömer TW, Müller CP. Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats. J Psychopharmacol. 2021 01; 35(1):65-77.
-
Bailey AM, Baum RA, Horn K, Lewis T, Morizio K, Schultz A, Weant K, Justice SN. Review of Intranasally Administered Medications for Use in the Emergency Department. J Emerg Med. 2017 Jul; 53(1):38-48.
-
Amato D, Pum ME, Groos D, Lauber AC, Huston JP, Carey RJ, de Souza Silva MA, Müller CP. Neuropharmacology of light-induced locomotor activation. Neuropharmacology. 2015 Aug; 95:243-51.
-
Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. J Pain Symptom Manage. 2014 Nov; 48(5):797-803.
-
Smith TJ, Ritter JK, Poklis JL, Fletcher D, Coyne PJ, Dodson P, Parker G. ABH gel is not absorbed from the skin of normal volunteers. J Pain Symptom Manage. 2012 May; 43(5):961-6.
-
McClure EA, Saulsgiver KA, Wynne CD. D-amphetamine, nicotine, and haloperidol produce similar disruptions in spatial and nonspatial temporal discrimination procedures. Behav Pharmacol. 2011 Apr; 22(2):101-12.
-
Amato D, Natesan S, Kapur S, Müller CP. Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. Behav Brain Res. 2011 Aug 01; 221(1):311-3.
-
Amato D, Natesan S, Yavich L, Kapur S, Müller CP. Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. Int J Neuropsychopharmacol. 2011 Nov; 14(10):1327-39.
-
Amato D, Stasi MA, Borsini F, Nencini P. Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia. Psychopharmacology (Berl). 2008 Oct; 200(2):157-65.
-
Arun P, Madhavarao CN, Moffett JR, Namboodiri AM. Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. J Neurochem. 2008 Aug; 106(4):1669-80.